PT-141

What PT-141 Does

PT-141 (bremelanotide) is a synthetic melanocortin peptide that enhances sexual desire by acting directly on the brain. Unlike Viagra and Cialis, which work mechanically by increasing blood flow to the genitals, PT-141 activates melanocortin-4 (MC4R) receptors in the hypothalamus — the brain region that regulates sexual arousal, motivation, and desire. It is FDA-approved as Vyleesi for women and used off-label for men.

The mechanisms that matter:

• MC4R activation in the hypothalamus — directly stimulates the neural pathways responsible for sexual arousal and desire. This is a central (brain) effect, not a peripheral (genital) effect
• Dopamine pathway modulation — increases dopaminergic activity in reward circuits, enhancing motivation and anticipation associated with sexual activity
• Works for both sexes — one of the few sexual health treatments effective in both men and women. FDA-approved for female HSDD, widely used off-label for male ED and low libido
• On-demand dosing — not a daily medication. Taken 45–60 minutes before anticipated activity, as needed

PT-141 vs PDE5 Inhibitors (Viagra/Cialis)

This is the critical distinction:

Feature	PT-141	Viagra/Cialis
Mechanism	Brain (melanocortin receptor)	Peripheral (PDE5 inhibition)
What it increases	Desire, arousal, libido	Blood flow to genitals
Works for low libido	Yes — primary indication	No — requires desire to be present
Works for ED	Yes (via increased arousal)	Yes (via mechanical blood flow)
Works for women	Yes (FDA-approved)	Limited evidence
Route	Subcutaneous injection	Oral pill
Onset	45–60 minutes	30–60 minutes
Duration	6–12 hours	4–36 hours (varies by drug)
Main side effect	Nausea	Headache, flushing

When to use PT-141: Low desire, low libido, “want to want it” situations, female sexual dysfunction, ED that doesn’t respond to PDE5 inhibitors alone, or combined with PDE5 inhibitors for comprehensive effect.

When to use PDE5 inhibitors: Purely mechanical ED with normal desire, performance-specific situations, convenience (oral dosing).

Dosing Protocol

Standard Protocol

Parameter	Detail
Dose	1,000–2,000 mcg (1–2 mg)
Timing	45–60 minutes before anticipated activity
Route	Subcutaneous injection (abdomen or thigh)
Max frequency	Once per 24 hours
Max doses per month	8 (FDA recommendation for Vyleesi)

Dose Selection

Dose	Use Case
500 mcg	Trial dose to assess tolerance (especially for nausea sensitivity)
1,000 mcg (1 mg)	Standard starting dose. Effective for most users with moderate side effects
1,750 mcg (1.75 mg)	FDA-approved Vyleesi dose. Good balance of efficacy and tolerability
2,000 mcg (2 mg)	Maximum recommended dose. Strongest effect but highest nausea risk

Start at 1,000 mcg. If well-tolerated but insufficiently effective, increase to 1,750–2,000 mcg next time. If nausea is significant at 1,000 mcg, drop to 500 mcg and consider anti-nausea premedication.

Timing Details

• Inject 45–60 minutes before. Allow time for the peptide to reach CNS melanocortin receptors.
• Effects peak at 1–3 hours and persist for 6–12 hours.
• Not dependent on food or fasting. No dietary restrictions.
• Alcohol is compatible in moderation. Heavy alcohol use may blunt the effect.

Reconstitution

For a 10 mg vial — add 5 mL bacteriostatic water:

Dose	Volume to Draw
500 mcg	25 units on insulin syringe
1,000 mcg (1 mg)	50 units
1,750 mcg (1.75 mg)	87.5 units
2,000 mcg (2 mg)	100 units (1 mL)

Concentration: 2,000 mcg/mL. One 10 mg vial provides 5–10 doses depending on dose used.

Storage: Refrigerate at 2–8°C. Use within 28 days of reconstitution. Unreconstituted powder can be stored in the freezer.

Managing Nausea

Nausea is the deal-breaker for many users. Here’s how to manage it:

1. Start low (500–1,000 mcg) — nausea is strongly dose-dependent
2. Anti-nausea premedication — ondansetron (Zofran) 4–8 mg taken 30 minutes before PT-141 injection is highly effective. OTC alternatives: ginger capsules (1,000 mg) or meclizine (25 mg)
3. Don’t inject on a full stomach — a light meal 1–2 hours before is fine, but heavy/fatty food worsens nausea
4. The nausea peaks and passes — typically worst at 1–2 hours post-injection, resolving by hour 3
5. Tolerance develops — many users report nausea decreasing with repeated use

What the Research Says

PT-141 has a solid clinical evidence base, including Phase 3 trials:

Female HSDD (RECONNECT trials, Phase 3): Bremelanotide 1.75 mg showed statistically significant improvement in sexual desire scores and reduction in distress associated with low sexual desire vs placebo. Results led to FDA approval of Vyleesi in 2019. Published in Obstetrics & Gynecology.

Male ED: A Phase 2 study of intranasal bremelanotide in men with ED showed significant improvement in erection quality vs placebo. The effect was most pronounced in men who had not responded to sildenafil (Viagra), suggesting a complementary mechanism. Published in Journal of Sexual Medicine.

Mechanism: Multiple studies confirm MC4R activation in the medial preoptic area and paraventricular nucleus of the hypothalamus — brain regions directly involved in sexual behavior regulation. This central mechanism is pharmacologically distinct from PDE5 inhibition.

Safety: The RECONNECT trials showed no cardiovascular risk signal. PT-141 causes a transient mild increase in blood pressure (1–3 mmHg) that resolves within hours. No clinically significant drug interactions were identified.

Safety

Common Side Effects

Side Effect	Frequency	Notes
Nausea	~40%	Dose-dependent, peaks at 1–2 hrs, resolves by 3 hrs
Flushing	~20%	Warmth and redness, typically facial. Transient
Headache	~10%	Usually mild
Injection-site reaction	~5%	Minor redness/soreness
Fatigue	~5%	May occur several hours post-dose

Important Warnings

Blood pressure. PT-141 causes a transient small increase in blood pressure. Uncontrolled hypertension is a contraindication. Monitor BP if you have hypertension history.

Skin darkening. PT-141 activates melanocortin receptors involved in melanin production. Prolonged, frequent use can cause hyperpigmentation (skin darkening), particularly facial, gum, and breast tissue. This effect is more pronounced with Melanotan II (a related peptide). With as-needed PT-141 dosing (not daily), significant darkening is uncommon.

Do not combine with Melanotan II. Both activate melanocortin receptors. Combining them amplifies side effects (nausea, BP increase, skin darkening) without additional sexual health benefit.

FDA limits frequency. The Vyleesi label recommends no more than 8 doses per month and no more than 1 dose per 24 hours. This is based on the safety profile — not because efficacy is lost, but to limit cumulative melanocortin stimulation.

Do Not Use If

• Uncontrolled hypertension
• History of cardiovascular events (MI, stroke)
• Concurrent use of Melanotan II
• Pregnant or breastfeeding
• Under 18

What Comes Next

• Explore other protocols matched to your goals in the Directory
• If also dealing with recovery issues — BPC-157 Protocol or the Wolverine Stack
• Use the Reconstitution Calculator for exact unit counts